Clinical and Non-Clinical Overviews: The Module 2 Documents Assessors Read First

Modules 4 and 5 hold the data, but Module 2 holds the argument. The non-clinical and clinical overviews are usually the first documents an assessor reads, and they set the tone for the whole assessment.

What the overviews are for

Under the Common Technical Document structure in ICH M4, Module 2 contains the quality overall summary, the non-clinical overview and summaries, and the clinical overview and summary. The overviews are critical analyses, not summaries. They must interpret the data, explain the strengths and limitations of the programme and reach reasoned conclusions on benefit and risk.

The overview should be written to be read on its own, by someone who will then use cross-references to check key points in the detailed reports.

The clinical overview

A good clinical overview presents the development rationale and the clinical programme, then discusses efficacy and safety and arrives at a benefit-risk conclusion that supports the proposed indication and product information. It should face difficult data openly: missing endpoints, protocol deviations, subgroup findings and safety signals.

  • Explain why the design and endpoints suit the claim.
  • Discuss consistency across studies, populations and regions.
  • Link the safety profile to the risk management plan.
  • Justify any deviation from relevant guidelines.

The non-clinical overview

This document should assess the pharmacology, pharmacokinetics and toxicology programme, and explain its relevance for human use. Where studies are absent, for example in a bibliographic or hybrid application, the overview must justify why. Expert qualifications and signed statements are expected.

Make sure the findings feed the product information, particularly for sections on pregnancy and fertility, and carcinogenicity.

Consistency is the quality test

The commonest weakness is mismatch: numbers in the overview that differ from the study reports, claims in the SmPC that the overview does not support, or conclusions that go beyond the data. A systematic cross-check of every figure and claim against source documents before filing prevents most of these.

Writing process and review

Allow enough time for the overviews. They should be drafted after the main study reports are final, but not left until the last week, because writing them often reveals inconsistencies that need corrections in other modules. Use a clear template that follows the ICH guidance, assign a medical or scientific lead for each, and plan an independent review. Align them with the proposed product information in parallel, so that each statement in the SmPC can be traced to the supporting analysis. Build the review of the overviews into the compile plan from the start.

How PQRA helps

PQRA can write or critically review non-clinical and clinical overviews, check them against the underlying reports and the draft product information, and coordinate with qualified experts who sign the statements.

Contact PQRA to discuss your dossier and procedure.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *